Quality measures

The AAD is working to expand the number and type of dermatology-specific measures available to dermatologists. Dermatology measures are needed to meet the reporting requirements for Centers for Medicare and Medicaid Services' (CMS) Physician Quality Reporting System (PQRS), which has transitioned to the Quality Payment Program in 2017. Measures are also needed for quality improvement efforts, particularly for the AAD’s dermatology clinical database registry DataDermTM.

Dermatology quality measures for MIPS

The Academy provides support with measure reporting to MIPS through the Academy’s DataDerm clinical registry. Through DataDerm, users can choose from dermatology-specific or dermatology-applicable measures to report for 2017 MIPS. CMS published the 2017 dermatology specialty measure set for MIPS. Find the dermatology specialty set measures that best fit your practice.

The AAD’s DataDerm™ clinical registry has been approved as a Qualified Clinical Data Registry (QCDR) for the 2017 reporting year! The QCDR designation allows DataDerm users the opportunity to report more dermatology specific measures that best fit their practice. DataDerm offers 22 MIPS measures, seven of which are AAD developed measures. Additionally, five AAD developed, derm-specific measures are also available for MIPS reporting. These measures are referred to as QCDR measures and are only available for reporting through DataDerm. Get more information about the five AAD QCDR measures available to DataDerm participants. If you are not a member of DataDerm and are interested in using these copyrighted measures, please contact Laura Vera.  

View MIPS derm set measures

View 2017 quality measures

How are measures developed
AAD measure development is led by the physicians on the Performance Measurement Committee (PMC). The PMC employs an evidence-based methodology to support measures with clinical practice guidelines, appropriate use criteria, and other evidence, such as data showing gaps in clinical care or the overuse of medical procedures or therapies. To determine priorities, the PMC periodically conducts a needs assessment and then develops measures with staff support. Measures then undergo peer review by AAD committees, councils, and finally, the Board of Directors. 

After approval, the measures are pilot tested with dermatology practices to determine validity, reliability, and feasibility. Measures are refined based on the results of testing and published.